Gangrene future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.
Overview
Overview
A novel gene therapeutic approach is currently conducted to promote reperfusion and angiogenesis of ischemic tissues, which can help in limb salvage. Ongoing study on this approach is conducted on mice and it involves the intramuscular injection of adeno-associated virus/ (AAV) vector, and E-selectin.
Future or Investigational Therapies
Future or Investigational Therapies
- More than 150,000 limb amputations due to gangrene are done yearly in the United States, despite medical and surgical interventions.
- A novel gene therapeutic approach is currently conducted to promote reperfusion and angiogenesis of ischemic tissues, which can help in limb salvage.
- Ongoing study on this approach is conducted on mice and it involves the intramuscular injection of adeno-associated virus/ (AAV) vector, and E-selectin. [1]
- Another new emerging therapy involves the endothelial progenitor cells /(EPC) which are commonly derived from peripheral blood or bone marrow. [2]
References
References
- ↑ Quiroz HJ, Parikh PP, Lassance-Soares RM, Regueiro MM, Li Y, Shao H; et al. (2021). “Gangrene, revascularization, and limb function improved with E-selectin/adeno-associated virus gene therapy”. JVS Vasc Sci. 2: 20–32. doi:10.1016/j.jvssci.2020.10.001. PMC 8489216 Check
|pmc=value (help). PMID 34617055 Check|pmid=value (help). - ↑ Wang ZX, Li D, Cao JX, Liu YS, Wang M, Zhang XY; et al. (2014). “Efficacy of autologous bone marrow mononuclear cell therapy in patients with peripheral arterial disease”. J Atheroscler Thromb. 21 (11): 1183–96. doi:10.5551/jat.23374. PMID 25078066.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH